Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2021-07-29 Interim / Quarterly Rep…
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2021 (period ending June 30, 2021). It includes a consolidated income statement, cash position analysis, and detailed management discussion regarding business activities, R&D programs (AsiDNA, OX400), and corporate governance. It is not a short announcement or a press release summary, but rather the full interim financial report itself, which fits the definition of an Interim / Quarterly Report (IR). H2 2021
2021-07-29 English
Informations privilégiées / Communiqué sur comptes, résultats
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2021 (1er semestre 2021) for Onxeo S.A. It includes detailed consolidated financial statements (income statement, balance sheet data), management's analysis of financial results, business highlights, and corporate governance updates. It is not a short announcement or a press release summary, but rather the full interim report containing substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-07-29 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled '2021 HALF-YEARLY FINANCIAL REPORT' and contains comprehensive financial statements, including a consolidated balance sheet, statement of comprehensive income, and notes to the financial statements for the period ending June 30, 2021. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H2 2021
2021-07-29 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2021' (Half-Year Financial Report 2021) for the company Onxeo. It contains a detailed summary, management discussion on activities, financial statements (consolidated balance sheet, income statement, cash flow), and notes to the financial statements. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-07-29 French
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document is an official announcement titled "Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company's Chairwoman of the Board." It details changes in the senior leadership/governance structure of the company, specifically the appointment of a new Chairwoman and the status of the outgoing Chairwoman. This content directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-07-29 English
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 1% confidence The document is a press release from Onxeo announcing a significant change in its leadership structure: the appointment of Dr. Shefali Agarwal as the new Chairman of the Board of Directors, while the outgoing chair remains on the board. This content directly relates to changes in the company's governing body and senior personnel. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a proxy statement (PSI).
2021-07-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.